Correction for Lees et al.,
(Stroke. 2001;32:2961.)
© 2001 American Heart Association, Inc.
In "Tolerability of the Low-Affinity, Use-Dependent NMDA Antagonist AR-R15896AR in Stroke Patients: A Dose-Ranging Study," by Lees et al, an error in the wording of a paragraph in the Results section was introduced during a revision of the manuscript. The paragraph (on page 470) should read as follows:
Stroke Outcome The numbers of patients achieving good outcome, as defined by 1-month Barthel score 95 to 100, 1-month modified Rankin scale of 0 to 1, or 1-week NIHSS 0 to 1, were 42, 39, and 25, respectively, for AR-R15896AR versus 22, 23, and 12 with placebo. Moderate outcome, as defined as Barthel score 60 to 90, modified Rankin scale 2 to 3, or NIHSS 2 to 8, was achieved in 24, 20, and 45 patients with AR-R15896AR and 12, 8, and 23, respectively, after placebo. There was no statistically significant difference between placebo and active groups with regard to any outcome.
The author of a recent editorial comment, "Investigating Acute Stroke: Does Invasive Monitoring Add to Identifying Patients at Risk for Progression?" was incorrectly identified.
The guest editor of the comment was Ashfaq Shuaib, MD.
Footnotes
[Correction for Vol 32, Number 2, February 2001. Pages 466–472.]
[Correction for Vol 32, Number 8, August 2001. Pages 1866–1867.]
| ||||||||||||||||||||||||||||||||||||||||||||